Cargando…

Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca

Synchronous bilateral breast cancers (SBBC) are characterized by extensive clinical and morphological heterogeneity, with an frequency between 1.5 and 3.2%. Women treated for unilateral breast cancer are at higher risk of developing contralateral breast cancer. Screening and advances in breast imagi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Ahmadaye Ibrahim, Bendahhou, Karima, Mestaghanmi, Houriya, Saile, Rachid, Benider, Abdellatif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325485/
https://www.ncbi.nlm.nih.gov/pubmed/28292084
http://dx.doi.org/10.11604/pamj.2016.25.121.9967
_version_ 1782510394346045440
author Khalil, Ahmadaye Ibrahim
Bendahhou, Karima
Mestaghanmi, Houriya
Saile, Rachid
Benider, Abdellatif
author_facet Khalil, Ahmadaye Ibrahim
Bendahhou, Karima
Mestaghanmi, Houriya
Saile, Rachid
Benider, Abdellatif
author_sort Khalil, Ahmadaye Ibrahim
collection PubMed
description Synchronous bilateral breast cancers (SBBC) are characterized by extensive clinical and morphological heterogeneity, with an frequency between 1.5 and 3.2%. Women treated for unilateral breast cancer are at higher risk of developing contralateral breast cancer. Screening and advances in breast imaging have improved detection rates of SBBC. Our study aims to analyze the epidemiological, clinical, histological and therapeutic features of bilateral breast cancer. We conducted a cross-sectional study of patients with breast cancer treated at the Mohammed VI Center over a two year period. Statistical analysis of the results was performed using R. software. 31 patients had SBBC, representing 2.4% of breast cancer cases in our Center. The average age was 47.8 ± 8.4 years, 22.6% of patients used oral contraceptives. A family history of breast cancer was observed in 22.6% of cases. The most common histological type was invasive ductal carcinoma (58.1%), SBR grade II and III were common (38.7%). Hormone receptors were positive for progesterone (38.7%) and for estrogen (41.9%). HER2 was overexpressed in 20.0% of cases. 29.0% of patients received hormonal therapy and 3.2% targeted therapies. Our study showed that bilateral breast cancer represents a small percentage of all breast cancers but have specific clinical features that help to differentiate it from unilateral breast cancer.
format Online
Article
Text
id pubmed-5325485
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-53254852017-03-10 Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca Khalil, Ahmadaye Ibrahim Bendahhou, Karima Mestaghanmi, Houriya Saile, Rachid Benider, Abdellatif Pan Afr Med J Case Series Synchronous bilateral breast cancers (SBBC) are characterized by extensive clinical and morphological heterogeneity, with an frequency between 1.5 and 3.2%. Women treated for unilateral breast cancer are at higher risk of developing contralateral breast cancer. Screening and advances in breast imaging have improved detection rates of SBBC. Our study aims to analyze the epidemiological, clinical, histological and therapeutic features of bilateral breast cancer. We conducted a cross-sectional study of patients with breast cancer treated at the Mohammed VI Center over a two year period. Statistical analysis of the results was performed using R. software. 31 patients had SBBC, representing 2.4% of breast cancer cases in our Center. The average age was 47.8 ± 8.4 years, 22.6% of patients used oral contraceptives. A family history of breast cancer was observed in 22.6% of cases. The most common histological type was invasive ductal carcinoma (58.1%), SBR grade II and III were common (38.7%). Hormone receptors were positive for progesterone (38.7%) and for estrogen (41.9%). HER2 was overexpressed in 20.0% of cases. 29.0% of patients received hormonal therapy and 3.2% targeted therapies. Our study showed that bilateral breast cancer represents a small percentage of all breast cancers but have specific clinical features that help to differentiate it from unilateral breast cancer. The African Field Epidemiology Network 2016-10-27 /pmc/articles/PMC5325485/ /pubmed/28292084 http://dx.doi.org/10.11604/pamj.2016.25.121.9967 Text en © Ahmadaye Ibrahim Khalil et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Series
Khalil, Ahmadaye Ibrahim
Bendahhou, Karima
Mestaghanmi, Houriya
Saile, Rachid
Benider, Abdellatif
Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca
title Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca
title_full Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca
title_fullStr Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca
title_full_unstemmed Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca
title_short Cancer du sein bilatéral synchrone: expériences du centre Mohammed VI pour le traitement des cancers CHU Ibn Rochd Casablanca
title_sort cancer du sein bilatéral synchrone: expériences du centre mohammed vi pour le traitement des cancers chu ibn rochd casablanca
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325485/
https://www.ncbi.nlm.nih.gov/pubmed/28292084
http://dx.doi.org/10.11604/pamj.2016.25.121.9967
work_keys_str_mv AT khalilahmadayeibrahim cancerduseinbilateralsynchroneexperiencesducentremohammedvipourletraitementdescancerschuibnrochdcasablanca
AT bendahhoukarima cancerduseinbilateralsynchroneexperiencesducentremohammedvipourletraitementdescancerschuibnrochdcasablanca
AT mestaghanmihouriya cancerduseinbilateralsynchroneexperiencesducentremohammedvipourletraitementdescancerschuibnrochdcasablanca
AT sailerachid cancerduseinbilateralsynchroneexperiencesducentremohammedvipourletraitementdescancerschuibnrochdcasablanca
AT beniderabdellatif cancerduseinbilateralsynchroneexperiencesducentremohammedvipourletraitementdescancerschuibnrochdcasablanca